ECSP10010555A - Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona - Google Patents

Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona

Info

Publication number
ECSP10010555A
ECSP10010555A EC2010010555A ECSP10010555A ECSP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC 2010010555 A EC2010010555 A EC 2010010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A
Authority
EC
Ecuador
Prior art keywords
quinolin
piperazin
fluoro
amino
methyl
Prior art date
Application number
EC2010010555A
Other languages
English (en)
Inventor
Danielle Giron
Frank Stowasser
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010555A publication Critical patent/ECSP10010555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas cristalinas o polimorfos de las sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-quinolin-2(1H)-ona, asi como metodos para la elaboracion de las mismas, composiciones farmaceuticas que comprenden las mismas, y metodos de tratamiento utilizando las mismas.
EC2010010555A 2008-03-19 2010-10-19 Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona ECSP10010555A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19

Publications (1)

Publication Number Publication Date
ECSP10010555A true ECSP10010555A (es) 2010-11-30

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010555A ECSP10010555A (es) 2008-03-19 2010-10-19 Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona

Country Status (24)

Country Link
US (1) US8563556B2 (es)
EP (1) EP2257544B1 (es)
JP (1) JP2011515370A (es)
KR (1) KR20100137517A (es)
CN (1) CN101970425B (es)
AR (1) AR070924A1 (es)
AU (1) AU2009227003B2 (es)
BR (1) BRPI0909762A2 (es)
CA (1) CA2718076A1 (es)
CL (1) CL2009000651A1 (es)
CO (1) CO6321253A2 (es)
EC (1) ECSP10010555A (es)
IL (1) IL208020A0 (es)
MA (1) MA32230B1 (es)
MX (1) MX2010010152A (es)
MY (1) MY150554A (es)
NZ (2) NZ600887A (es)
PE (1) PE20091628A1 (es)
PH (2) PH12012502569A1 (es)
RU (1) RU2497820C2 (es)
SG (1) SG188919A1 (es)
TW (1) TWI426072B (es)
WO (1) WO2009115562A2 (es)
ZA (1) ZA201006263B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
JP2013525292A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 有機化合物の組合せ
EP2558095B1 (en) 2010-04-16 2018-10-24 Novartis AG Organic compound for use in the treatment of liver cancer
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US20130345234A1 (en) 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
BR112014005653A2 (pt) 2011-09-15 2017-03-28 Novartis Ag uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140117457A (ko) 2012-01-31 2014-10-07 노파르티스 아게 Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
RU2015104537A (ru) 2012-07-11 2016-08-27 Новартис Аг Способы лечения стромальных опухолей желудочно-кишечного тракта
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4361727B2 (ja) * 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
TWI347940B (en) * 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
US20060183750A1 (en) * 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
BRPI0619370A2 (pt) * 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
RU2497820C2 (ru) 2013-11-10
SG188919A1 (en) 2013-04-30
MY150554A (en) 2014-01-30
JP2011515370A (ja) 2011-05-19
CN101970425A (zh) 2011-02-09
NZ587829A (en) 2012-08-31
BRPI0909762A2 (pt) 2018-04-03
CA2718076A1 (en) 2009-09-24
CO6321253A2 (es) 2011-09-20
PH12012502569A1 (en) 2015-09-21
ZA201006263B (en) 2011-05-25
CL2009000651A1 (es) 2010-07-19
HK1147492A1 (en) 2011-08-12
KR20100137517A (ko) 2010-12-30
US20110021536A1 (en) 2011-01-27
AR070924A1 (es) 2010-05-12
MX2010010152A (es) 2010-10-25
NZ600887A (en) 2013-10-25
MA32230B1 (fr) 2011-04-01
US8563556B2 (en) 2013-10-22
PH12012502568A1 (en) 2014-10-27
EP2257544B1 (en) 2014-12-03
CN101970425B (zh) 2014-04-16
RU2010142396A (ru) 2012-04-27
WO2009115562A2 (en) 2009-09-24
EP2257544A2 (en) 2010-12-08
AU2009227003B2 (en) 2013-03-14
IL208020A0 (en) 2010-12-30
TW201000463A (en) 2010-01-01
AU2009227003A1 (en) 2009-09-24
WO2009115562A3 (en) 2009-11-26
PE20091628A1 (es) 2009-11-19
TWI426072B (zh) 2014-02-11

Similar Documents

Publication Publication Date Title
CO6321253A2 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4- amino-5- fluoro-3-[5-(4-metil-piperazin-1-il)1h-bencimidazol-2-il]-quinolin-2(1h)-ona
CL2015003442A1 (es) Derivados heterociclicos
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
CL2007003671A1 (es) Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
BR112012031981A2 (pt) composição aquosa de ingrediente ativo, processo, uso, método para controlar fungos fitopatogênicos e semente
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
UY34070A (es) Método y composición para tratamiento de semillas.
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis